Effect of omega-3 on heart disease is negligible, finds Cochrane review

Effect of omega-3 on heart disease is negligible, finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

Welsh National Survey includes OTC medicine purchases for first time

Welsh National Survey includes OTC medicine purchases for first time

June 28 2018 Over half the population in Wales has reported having bought an over the counter...

Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

Bath emollients have ‘no benefit beyond standard eczema care for children’

Bath emollients have ‘no benefit beyond standard eczema care for children’

May 9 2018 A study has found no evidence of clinical benefit from including bath emollients in...

  • Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Thursday, 19 July 2018 10:21
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:32
  • Welsh National Survey includes OTC medicine purchases for first time

    Welsh National Survey includes OTC medicine purchases for first time

    Thursday, 28 June 2018 16:55
  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29
  • Bath emollients have ‘no benefit beyond standard eczema care for children’

    Bath emollients have ‘no benefit beyond standard eczema care for children’

    Wednesday, 09 May 2018 15:28

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

paracetamol pillsMarch 23 2016

Paracetamol on its own has no role in treating patients with osteoarthritis irrespective of dose, a review of scientific literature has concluded. However, diclofenac 150mg/day was considered the most effective non-steroidal anti-inflammatory drug both in terms of improving pain and function.

The Lancet study included 74 randomised trials covering data from a total of 58,556 patients. It found evidence to support the effectiveness of diclofenac 150mg/day, etoricoxib 30mg/day, 60mg/day, and 90mg/day, and rofecoxib 25mg/day and 50mg/day. It also found that the best interventions were diclofenac 150 mg/day and etoricoxib 60mg/day.

The researchers also found that treatment effects increased as drug dose increased, but a liner dose effect was only significant for celecoxib, diclofenac and naproxen. They also found no evidence that treatment effects varied over the duration of the treatment.

Commenting on the findings, the OTC trade body, the Proprietary Association of Great Britain, noted that the study had found all preparations improved patients’ symptoms of pain compared to placebo.

John Smith, PAGB Chief Executive, commented: “Paracetamol has been on the market for more than 50 years and is a safe and effective treatment for mild to moderate pain relief. NICE guidelines recommend paracetamol as a first line pain relief drug for osteoarthritis.

“It is important to note that the authors of this study identified limitations in the quality of analysis, due to the data available. It is unclear whether investigators in some trials were properly blinded and most trials had a high risk of incomplete outcome data bias, therefore further research is needed to draw any firm conclusions.

“We would advise anyone who is concerned about the use of paracetamol to speak to their pharmacist in the first instance. Pharmacists are highly trained healthcare professionals and can provide useful information and advice on over-the-counter painkillers.”

The Royal College of General Practitioners said the research added to the evidence around whether paracetamol was effective in osteoarthritis. Dr Maureen Baker, RCGP Chair, said: “The majority of evidence still suggests that paracetamol is a safe drug for most patients, but a number of recent studies – today’s included - do cast doubt on its effectiveness at treating osteoarthritis.

“What the study doesn’t suggest is a suitable – and safe – alternative for pain management in patients with osteoarthritis. We know that alternatives, such as NSAIDs, can be effective but they can have nasty side-effects for patients if they are taken over a long period of time. And whilst GPs understand and advocate lifestyle changes to patients, that can help ease their pain, there is a limit to how viable these are, particularly in serious cases.”

Dr Baker added that it was important that as new research is published, it is taken on board as guidelines for healthcare professionals are updated.

Links:

BR da Cosat et al. ‘Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis’. Lancet 2016. Published online March 17 2016

PAGB response

RCGP comment

OTC News

July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued.
July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued. The MHRA has launched the consultation with...